Deseret Mutual Benefit Administrators Buys 242 Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Deseret Mutual Benefit Administrators grew its position in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 16.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,753 shares of the company’s stock after buying an additional 242 shares during the quarter. Deseret Mutual Benefit Administrators’ holdings in GE HealthCare Technologies were worth $165,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in GE HealthCare Technologies by 9.2% in the first quarter. Vanguard Group Inc. now owns 48,519,340 shares of the company’s stock valued at $4,410,893,000 after acquiring an additional 4,107,746 shares during the period. Bank of Montreal Can increased its position in shares of GE HealthCare Technologies by 27.5% during the 2nd quarter. Bank of Montreal Can now owns 696,446 shares of the company’s stock valued at $54,964,000 after purchasing an additional 150,137 shares during the last quarter. Sei Investments Co. lifted its stake in shares of GE HealthCare Technologies by 30.6% in the 1st quarter. Sei Investments Co. now owns 279,336 shares of the company’s stock worth $25,393,000 after purchasing an additional 65,476 shares during the period. Douglas Lane & Associates LLC boosted its holdings in shares of GE HealthCare Technologies by 2.2% in the third quarter. Douglas Lane & Associates LLC now owns 460,004 shares of the company’s stock worth $43,171,000 after buying an additional 10,099 shares during the last quarter. Finally, Canada Pension Plan Investment Board grew its position in GE HealthCare Technologies by 5,075,130.0% during the first quarter. Canada Pension Plan Investment Board now owns 507,523 shares of the company’s stock valued at $46,139,000 after buying an additional 507,513 shares during the period. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

GE HealthCare Technologies Price Performance

GEHC stock opened at $86.94 on Thursday. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.98 and a current ratio of 1.23. The company’s fifty day moving average price is $88.80 and its 200-day moving average price is $83.48. GE HealthCare Technologies Inc. has a one year low of $66.39 and a one year high of $94.55. The company has a market capitalization of $39.72 billion, a PE ratio of 23.84, a price-to-earnings-growth ratio of 3.12 and a beta of 1.24.

GE HealthCare Technologies (NASDAQ:GEHC) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $1.14 EPS for the quarter, topping the consensus estimate of $1.06 by $0.08. The business had revenue of $4.86 billion for the quarter, compared to analysts’ expectations of $4.87 billion. GE HealthCare Technologies had a net margin of 8.56% and a return on equity of 25.19%. The business’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.99 EPS. On average, equities analysts anticipate that GE HealthCare Technologies Inc. will post 4.29 EPS for the current fiscal year.

GE HealthCare Technologies Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, November 15th. Shareholders of record on Friday, October 18th will be issued a dividend of $0.03 per share. This represents a $0.12 annualized dividend and a yield of 0.14%. The ex-dividend date is Friday, October 18th. GE HealthCare Technologies’s dividend payout ratio is presently 3.30%.

Insiders Place Their Bets

In other news, CEO Roland Rott sold 3,577 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $86.48, for a total transaction of $309,338.96. Following the completion of the transaction, the chief executive officer now directly owns 24,298 shares in the company, valued at approximately $2,101,291.04. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.27% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Redburn Atlantic upgraded shares of GE HealthCare Technologies to a “strong-buy” rating in a research report on Thursday, August 1st. Stifel Nicolaus raised their target price on GE HealthCare Technologies from $100.00 to $102.00 and gave the stock a “buy” rating in a report on Monday, September 30th. BTIG Research raised GE HealthCare Technologies from a “neutral” rating to a “buy” rating and set a $100.00 price target for the company in a report on Wednesday, September 18th. Evercore ISI raised their price objective on GE HealthCare Technologies from $98.00 to $102.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Finally, JPMorgan Chase & Co. started coverage on shares of GE HealthCare Technologies in a report on Monday, September 9th. They issued a “neutral” rating and a $90.00 target price for the company. One research analyst has rated the stock with a sell rating, five have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $94.36.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.